|By PR Newswire||
|February 19, 2014 02:29 PM EST||
- Focus on disease prevention coupled with an anticipated rise in the number of elderly people will aid market development
SAO PAULO, Feb. 19, 2014 /PRNewswire/ -- Investments in healthcare by the government to prevent diseases and promote health is fuelling the uptake of in vitro diagnosis (IVD) reagent kits in Brazil. The popularity of evidence-based medicine and the pressure to reduce costs in the Brazilian healthcare system are reinforcing this trend. To further strengthen the healthcare industry, the government has implemented incentive programs that encourage local manufacture of IVD equipment and reagent kits and reduce the country's dependence on imported products.
New research from Frost & Sullivan (http://www.lifesciences.frost.com), Analysis of the Brazilian Market for Reagent Kits in In Vitro Diagnosis, finds that the market earned revenues of $1.01 billion in 2012 and estimates this to reach $1.52 billion in 2017. The research covers the immunochemistry, microbiology, hematology/hemostasis, molecular diagnosis, urinalysis, and point-of-care testing (POCT) application segments. Although POCT accounted for only one percent of the total market share in 2012, the segment is expected to develop considerably over the forecast period.
"The increase of investments by the Brazilian Federal Government in the healthcare area, the growing cohort of elderly people and healthcare concerns are widening the potential of the market for reagent kits in IVD in Brazil," said Frost & Sullivan Healthcare Senior Industry Analyst Israel Nena. "The number of aged people is expected to go up from the current 23.5 million to nearly 63 million in 2050."
However, the host of taxes levied on reagent kits in IVD is increasing the price of these products, in turn, hindering uptake. Taxes alone can account for 70-100 percent of the invoice price, on top of which freight, insurance and import duties are added.
The market is also being challenged by new legislation (resolution 25/2010), which requires all IVD manufacturing plants to receive the good manufacturing practices certification. This is delaying the approval of reagent kits and equipment as the regulatory authority lacks sufficient personnel to inspect manufacturing sites within a reasonable timeframe.
In addition, the diagnosis laboratories market is witnessing consolidation. The three largest clinical laboratories – DASA Diagnostic Laboratory Group, Grupo Fleury and Hermes Pardini – held a combined market share of 30 percent in 2012. With these companies looking to participate in more mergers and acquisitions, the price erosion of IVD products will continue. Pressure exerted by the public sector through purchase bids will aggravate the drop in product prices.
"To remain competitive, Brazilian IVD companies need to obtain the technology to manufacture reagent kits with a higher value such as markers for tumors and molecular biology tests," noted Nena. "Some Brazilian companies have already signed partnership agreements with foreign IVD companies."
In fact, the market is being shaped by the recent interest of foreign companies to enter the Brazilian market for reagent kits in IVD to cater to promising but underdeveloped segments such as molecular diagnosis and POCT.
If you are interested in more information on this research, please send an email to Francesca Valente, Corporate Communications, at [email protected], with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
Analysis of the Brazilian Market for Reagent Kits in In Vitro Diagnosis is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related research services include: Global Tissue Diagnostics Market, Global Next Generation Sequencing Informatics Market, and MicroRNA Tools and Services Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Analysis of the Brazilian Market for Reagent Kits in In Vitro Diagnosis
Corporate Communications – Latin America
E: [email protected]
Dec. 8, 2016 09:45 PM EST Reads: 1,233
Dec. 8, 2016 09:15 PM EST Reads: 1,666
Dec. 8, 2016 09:15 PM EST Reads: 949
Dec. 8, 2016 08:30 PM EST Reads: 1,884
Dec. 8, 2016 07:45 PM EST Reads: 315
Dec. 8, 2016 07:15 PM EST Reads: 375
Dec. 8, 2016 06:45 PM EST Reads: 950
Dec. 8, 2016 05:45 PM EST Reads: 948
Dec. 8, 2016 05:45 PM EST Reads: 1,720
Dec. 8, 2016 05:00 PM EST Reads: 1,819
Dec. 8, 2016 04:45 PM EST Reads: 1,846
Dec. 8, 2016 04:45 PM EST Reads: 2,251
Dec. 8, 2016 04:30 PM EST Reads: 389
Dec. 8, 2016 04:30 PM EST Reads: 1,973
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Dec. 8, 2016 04:15 PM EST Reads: 311